Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Advanced Renal Cell Carcinoma — Systemic Therapy

First-line Second-line SECOND-LINE Advanced RCC clear cell 1L — IMDC favorable 1L — intermediate / poor Non-clear-cell Later-line IO + TKI Pembrolizumab + axitinib KEYNOTE-426 ↗ IO + TKI Pembrolizumab + lenvatinib CLEAR ↗ IO + TKI Nivolumab + cabozantinib CheckMate 9ER ↗ Dual-IO Ipilimumab + nivolumab CheckMate 214 ↗ IO + TKI IO + TKI combination any risk group ↗ TKI Cabozantinib METEOR ↗ IO Pembrolizumab-based / trial KEYNOTE-426 ↗ TKI Cabozantinib METEOR ↗ Combo Lenvatinib + everolimus Study 205 ↗ TKI Tivozanib TIVO-3 ↗ HIF-2α Belzutifan LITESPARK-005 ↗